Trump’s pharma tariffs put Singapore at ‘greatest risk’ among major exporters if no exemptions granted: economists
Without exemptions, the effective tariff rate on the Republic’s shipments could exceed 30%, compared with 4% now
Add BT as a preferred source
[SINGAPORE] The Trump administration’s latest tariff salvo – this time aimed at branded or patented pharmaceutical goods – could hit Singapore particularly hard, economists warned.
On Thursday (Sep 25), Trump announced a 100 per cent tariff on imports of branded or patented pharmaceutical goods from Oct 1, unless a company has already begun construction of a plant in the United States.
Pharmaceutical firms that have broken ground on US facilities will receive exemptions, Trump said.
TRENDING NOW
Abandoned ‘Titanic’, failing ‘ancient towns’: Why China’s tourism boom leaves white elephants behind
‘I felt like dying’: Thai Singha beer scion speaks up after disclosure of alleged sexual abuse
‘Very low chance’ that US-Iran deal reverts energy flows to South-east Asia through Hormuz: Bloomberg Economics
Battle for Asia’s ultra-rich: ‘Singapore can’t afford to keep losing clients to Dubai, Hong Kong’
